Iovance appoints Corleen Roche as CFO effective August 6, 2025

IOVANCE BIOTHERAPEUTICS, INC.

Corleen Roche, former CFO of CG Oncology and Immunome, replaces Matthew Rosinack as Principal Financial Officer.
Base salary of $600,000, one-time sign-on bonus of $50,000, and annual bonus target of 45% of base salary.
Receives 300,000 stock options and 150,000 RSUs, each vesting over 4 years with quarterly vesting after first anniversary.
Severance upon qualifying termination includes 12 months salary, pro-rated bonus, and accelerated equity vesting.

item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.